Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3β kinase: Implications for Alzheimer's disease

Molecular Psychiatry

Volumn 22, Issue 7, 2017, Pages 1002-1008

  Chu, J ^a   Lauretti, E ^a   Pratico D ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; SMALL INTERFERING RNA; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GLYCOGEN SYNTHASE KINASE 3; ONCOPROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; BRAIN; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; TAUOPATHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MICE; MICE, TRANSGENIC; NEURONS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TAU PROTEINS; TAUOPATHIES;

EID: 85010931713     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.214     Document Type: Article

References (44)

1. Giannopoulos PG, Praticò D. Alzheimer's disease. In: Colin R, Martin, Victor Reddy (eds). Diet and Nutrition in Dementia and Cognitive Decline. Chapter 2. Elsevier Publisher, 2015, pp 13-21.
2. Gandy S. Lifelong management of amyloid beta metabolism to prevent Alzheimer's disease. N Engl J Med 2012; 367: 864-866.
3. Chang HY, Yang X. Proteases for cell suicide: Functions and regulation of caspases. Microbiol Mol Biol Rev 2000; 64: 821-846.
4. Mc Laughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, et al. Caspase 3 activation is essential for neuroprotection in preconditioning. Proc Natl Acad Sci USA 2003; 100: 715-720.
5. Yang SY, Bolvin C, Sales KM, Fuller B, Seifalian AM, Winslet MC. IGF-I activates caspases 3/7, 8 and 9 but does not induce cell death in colorectal cancer cells. BMC Cancer 2009; 9: 1-12.
6. Fernando P, Kelly JF, Balazsi K, Slack RS, Megeney LA. Caspase 3 activity is required for skeletal muscle differentiation. Proc Natl Acad Sci USA 2002; 99: 11025-11030.
7. Launay S, Hermine O, Fontenay M, Kroemer G, Solary E, Garrido C. Vital functions for lethal caspases. Oncogene 2005; 24: 5137-5148.
8. Sztiller-Sikorska M, Jakubowska J, Wozniak M, Stasiak M, Czyz M. A non-apoptotic function of caspase-3 in pharmacologically-induced differentiation of K562 cells. Br J Pharmacol 2009; 157: 1451-1462.
9. Zermati Y, Garrido C, Amsellem S, Fishelson S, Bouscary D, Valensi F, et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med 2001; 193: 247-254.
10. Aispuru GR, Aguirre MV, Aquino-Esperanza JA, Lettieri CN, Juaristi JA, Brandan NC. Erythroid expansion and survival in response to acute anemia stress: The role of EPO receptor, GATA-1, Bcl-x L and caspase-3. Cell Biol Int 2008; 32: 966-978.
11. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999; 97: 395-406.
12. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, et al. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 2001; 158: 189-198.
13. Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW. Activated caspase-3 expression in Alzheimer's and aged control brain: Correlation with Alzheimer pathology. Brain Res 2001; 898: 350-357.
14. Gastard MC, Troncoso JC, Koliatsos VE. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 2003; 54: 393-398.
15. Zhao M, Su J, Head E, Cotman CW. Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol Dis 2003; 14: 391-403.
16. Ayala-Grosso C, Ng G, Roy S, Robertson GS. Caspase-cleaved amyloid precursor protein in Alzheimer's disease. Brain Pathol 2002; 12: 430-444.
17. Chu J, Li JG, Joshi YB, Giannopoulos PF, Hoffman NE, Madesh M, et al. Gamma secretase-activating protein is a substrate for caspase-3: Implications for Alzheimer's disease. Biol Psychiatry 2015; 77: 720-728.
18. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004; 114: 121-130.
19. Kolarova M, Garciá-Sierra F, Bartos A, Ricny J, Ripova D. Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012; 2012: 731526.
20. Chu J, Praticò D. 5-Lipoxygenase as an endogenous modulator of amyloid-formation in vivo. Ann Neurol 2011; 69: 34-46.
21. Chu J, Lauretti E, Craige CP, Praticò D. Pharmacological modulation of GSAP reduces amyloid-ß levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles. J Alzheimers Dis 2014; 41: 729-737.
22. Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Praticò D. 5-Lipoxygenase gene transfer worsens memory, amyloid, tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol 2012; 72: 442-454.
23. Giannopoulos PF, Chu J, Joshi YB, Sperow M, Li JG, Kirby LG, et al. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. Mol Psychiatry 2014; 19: 511-518.
24. Kishi T, Hirooka Y, Konno S, Ogawa K, Sunagawa K, Angiotensin II. Type 1 receptor-activated caspase-3 through ras/mitogen-activated protein kinase/extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympatho-excitation in stroke-prone spontaneously hypertensive rats. Hypertension 2010; 55: 291-297.
25. Stepanichev MY, Kudryashova IV, Yakovlev AA, Onufriev MV, Khaspekov LG, Lyzhin AA, et al. Central administration of a caspase inhibitor impairs shuttle-box performance in rats. Neuroscience 2005; 136: 579-591.
26. Giannopoulos PF, Yash BJ, Chu J, Praticò D. The 12/15lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo. Aging Cell 2013; 12: 1082-1090.
27. Feng ZC, Donnelly L, Li J, Krishnamurthy M, Riopel M, Wang R. Inhibition of Gsk3 activity improves-cell function in c-Kit Wv/+ male mice. Lab Invest 2012; 92: 543-555.
28. Bredesen DE, John V, Galvan V. Importance of the caspase cleavage site in amyloid-protein precursor. J Alzheimers Dis 2010; 22: 57-63.
29. Kim Y, Choi H, Lee W, Park H, Kam TI, Hong SH, et al. Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model. Neurobiol Dis 2016; 87: 19-28.
30. Troy CM, Jean YY. Caspases: Therapeutic targets in neurologic disease. Neurotherapeutics 2015; 12: 42-48.
31. D'Amelio M, Sheng M, Cecconi F. Caspase-3 in the central nervous system: Beyond apoptosis. Trends Neurosci 2012; 35: 700-709.
32. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 2011; 14: 69-76.
33. Del Campo M, Oliveira CR, Scheper W, Zwart R, Korth C, Müller-Schiffmann A, et al. BRI2 ectodomain affects A42 fibrillation and tau truncation in human neuroblastoma cells. Cell Mol Life Sci 2015; 72: 1599-1611.
34. Reifert J, Hartung-Cranston D, Feinstein SC. Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation. J Biol Chem 2011; 286: 20797-20811.
35. Endo H, Nito C, Kamada H, Nishi T, Chan PH. Activation of the Akt/GSK3beta signaling pathway mediated survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats. J Cereb Blood Flow Metab 2006; 26: 1479-1489.
36. Franke TF, Kaplan DR, Cantley LC. PI3K: Downstream AKT ion blocks apoptosis. Cell 1997; 88: 435-437.
37. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science 1997; 275: 665-668.
38. Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
39. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and-independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001; 11: 297-305.
40. Lee CW, Lau KF, Miller CC, Shaw PC. Glycogen synthase kinase-3beta-mediated tau phosphorylation in cultured cell lines. Neuroreport 2003; 14: 257-260.
41. Mercado-Gomez O, Hernadez-Fonseca K, Villavicencio-Quejeiro A, Massieu L, Chimal-Monroy J, Arias C. Inhibition of Wnt and PI3K signaling modulates GSK3-beta activity and induces morphological changes in cortical neurons: Role of tau phosphorylation. Neurochem Res 2008; 33: 1599-1609.
42. Cheng B, Martinez AA, Morado J, Scofield V, Roberts JL, Maffi SK. Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway. Neurochem Int 2013; 62: 31-42.
43. Verspurten J, Gevaert K, Declercq W, Vandenabeele P. Site predicting the cleavage of proteinase substrates. Trends Biochem Sci 2009; 34: 319-323.
44. Jiang J, Wang ZH, Qu M, Gao D, Liu X-P, Zhu L-Q, et al. Stimulation of Eph B2 attenuates tau phosphorylation through PI3K-Akt-mediated inactivation of glycogen synthase kinase-3. Sci Rep 2015; 5: 11765.